Indeed, the significant overlap between FOXC1 binding sites and increased chromatin accessibility in SP cells suggests that FOXC1 may act as a pioneer transcription factor in bladder cancer cells that transition to cisplatin resistance. Here, FOXC1 is linked to urinary bladder carcinoma.